Rapid Death during Cocaine Abuse: A Variant of the Neuroleptic Malignant Syndrome?

References

• Strategy Council on Drug Abuse. Federal Strategy for Drug Abuse and Drug Traffic Prevention 1973, Superintendent of Documents. U.S. Government Printing Office, Washington, D.C. 1973
   Google Scholar
• Mittleman R., Wetli C. V. Death caused by recreational cocaine use. J. Am. Med. Assoc 1984; 252: 1889–1892
   PubMed Web of Science ®Google Scholar
• Fishbain D. A., Wetli C. V. Cocaine intoxication, delirium, and death in a body packer. Ann. Emerg. Med 1981; 10: 531–532
   PubMed Web of Science ®Google Scholar
• Wetli C. V., Wright R. K. Death caused by recreational cocaine use. J. Am. Med. Assoc 1979; 241: 2519–2522
   PubMed Web of Science ®Google Scholar
• Wetli C. V., Fishbain D. A. Cocaine induced psychosis and sudden death in recreational cocaine users. J. Forensic Sci 1985; 30: 873–880
   PubMed Web of Science ®Google Scholar
• Jaffe J. H. Drug addiction and drug abuse. The Pharmacological Basis of Therapeutics, A. G. Gilman, L. S. Goodman, A. Gilman. Macmillan, New York 1980; 535–584
   Google Scholar
• Smart R. G., Anglin L. Do we know the lethal dose of cocaine?. J. Forensic Sci 1987; 32: 303–312
   PubMed Web of Science ®Google Scholar
• Baselt R. C. Disposition of Toxic Drugs and Chemicals in Man2nd ed. Biomedical Publications, Davis, California 1982; 193–198
   Google Scholar
• VanDyke C., Byck R. Cocaine: 1884–1974. Cocaine and Other Stimulants, E. H. Ellinwood, M. M. Kilby. Plenum, New York 1976; 1–30
   Google Scholar
• Levinson J. L. Neuroleptic malignant syndrome. Am. J. Psychiatry 1985; 142: 1137–1145
   PubMedGoogle Scholar
• Pope H. G., Keck P. E., McElroy S. L. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am. J. Psychiatry 1986; 143: 1227–1232
   PubMed Web of Science ®Google Scholar
• Friedman J. H., Feinberg S. S., Feldman R. G. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. J. Am. Med. Assoc 1985; 254: 2792–2795
   PubMed Web of Science ®Google Scholar
• Burke R., Fahn S., Mayeux R., et al. Neuroleptic malignant syndrome caused by dopamine depleting agents in a patient with Huntington's disease. Neurology 1981; 31: 1022–1026
   PubMed Web of Science ®Google Scholar
• Figa‐Talamanca L., Gualandi C., DiMeo L., et al. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: Impaired dopamine receptor a possible cause. Neurology 1985; 35: 258–261
   PubMed Web of Science ®Google Scholar
• Henderson V. W., Wooten G. F. Neuroleptic malignant syndrome: A pathogenic role for dopamine receptor blockade?. Neurology 1981; 31: 132–137
   PubMed Web of Science ®Google Scholar
• Pletscher A., Brossi A., Gey K. F. Benzoquinolizine derivatives: A new class of monamine decreasing drugs with psychotropic action. Int. Rev. Neurobiol 1962; 4: 275–306
   Web of Science ®Google Scholar
• Price L. H., Charney D. S., Heninger G. R. Reserpine augmentation of desipramine in refractory depression: Clinical and neurobiological effects, Under Review
   Google Scholar
• Taylor D. L., Ho B. T. Neurochemical effects of cocaine following acute and repeated injection. J. Neurosci. Res 1977; 3: 95–101
   PubMed Web of Science ®Google Scholar
• Gold M. S., Dackis C. A. New insights and treatment: Opiate withdrawal and cocaine addiction. Clin. Ther 1984; 7: 6–21
   PubMed Web of Science ®Google Scholar
• Auzepy P., Poivet D., Nitenberg G. Insufisance repiratoire aigue chez deux schizophrenes: Role eventuel des neuroleptiques retard. Nouv. Presse. Med 1977; 6: 1236
   Google Scholar
• Fabre S., Gervais C., Manuel C., et al. Le syndrome des neuroleptiques: A propos de 7 cas. Encephale 1977; 3: 321–326
   PubMedGoogle Scholar
• Lipton J. M., Clark W. G. Neurotransmitters in temperature control. Annu. Rev. Physiol 1986; 48: 613–623
   PubMed Web of Science ®Google Scholar
• Clark G., Magoun H. W., Ranson S. W. Hypothalamic regulation of body temperature. J. Neurophysiol 1939; 2: 61–80
   Google Scholar
• Lin M. T. Effects of dopaminergic antagonist and agonist on thermoregulation in rabbits. J. Physiol. (London) 1979; 293: 217–228
   Google Scholar
• Yehuda S., Wurtman R. J. Dopaminergic neurons in the nigrostriatal and mesolimbic pathways: Mediation of specific effects of D‐amphetamine. Eur. J. Pharmacol 1975; 30: 154–158
   PubMed Web of Science ®Google Scholar
• Gilat G., Shibolet S., Sohar E. The mechanism of heatstroke. J. Trop. Med. Hy 1963; 66: 204–212
   PubMedGoogle Scholar
• Cox B., Lee T. F. Location of receptors mediating hypothermia after injection of dopamine agonists in rats. Br. J. Pharmacol 1977; 59: 467P–468P
   Google Scholar
• Barnett A., Goldstein J., Taber R. I. Apomorphine induced hypothermia in mice: A possible dopaminergic effect. Arch. Int. Pharmacodyn. Ther 1972; 198: 242–247
   PubMedGoogle Scholar
• Kruk Z. L. The effect of drugs acting on dopamine receptors on the body temperature of the rat. Life Sci 1972; 11: 845–850
   Google Scholar
• Wise R. A. Neural mechanisms of the reinforcing action of cocaine. Cocaine: Pharmacology, Effects and Treatment of Abuse, J. Grabowski. National Institute on Drug Abuse, Rockville, Maryland 1984; 15–33
   Google Scholar
• Gunne L. M., Anggard E., Jonsson L. E. Clinical trials with amphetamine blocking drugs. Psychiatr., Neurol., Neurochir 1972; 75: 225–226
   PubMedGoogle Scholar
• Carlsson A. Mechanism of action of neuroleptic drugs. Psychopharmacology: A Generation of Progress, M. A. Lipton, A. DiMascio, K. F. Killiam. Raven, New York 1978; 1057–1070
   Google Scholar
• Hornykiewicz O. Parkinson's disease: From brain homogenates to treatment. Fed. Proc 1973; 32: 183–190
   PubMedGoogle Scholar
• Heikkila R. E., Orlansky H., Cohen G. Studies on the distinction between uptake inhibition and release on (3H) dopamine in rat tissue slices. Biochem. Pharmacol 1975; 24: 847–852
   PubMed Web of Science ®Google Scholar
• VanDyke C., Jatlow P., Ungerer J., et al. Oral cocaine: Plasma concentrations and central effects. Science 1978; 200: 211–213
   PubMedGoogle Scholar
• Taylor D. L., Ho B. T., Fagan J. D. Increased dopamine receptor binding in rat brain by repeated cocaine injections. Commun. Psychopharm 1979; 3: 137–142
   PubMedGoogle Scholar
• Memo M., Pradhan S., Hanbauer I. Cocaine induced supersensitivity of striatial dopamine receptors: Role of endogenous calmodulin. Neuropharmacology 1981; 20: 1145–1150
   PubMedGoogle Scholar
• Post R. M. Frontiers in affective disorder research: New pharmacological agents and new metholologies. Psychopharmacology: A Generation of Progress, M. A. Lipton, A. DiMascio, K. F. Killam. Raven, New York 1978; 1323–1335
   Google Scholar
• Yamawaki S., Lai H., Horita A. Dopaminergic and serotonergic mechanisms of thermoregulation: Mediation of thermal effects of apomorphine and dopamine. J. Pharmacol. Exp. Ther 1983; 227: 383–388
   PubMedGoogle Scholar
• Danielson T. J., Coutts R. T., Coutts K. A., et al. Reserpine induced hypothermia and its reversal by dopamine agonists. Life Sci 1985; 37: 31–38
   PubMed Web of Science ®Google Scholar
• Marques P. R., Spencer R. L., Burks T. F., et al. Behavioral thermoregulation, core temperature, and motor activity: Simultaneous quantitative assessment in rats after dopamine and prostaglandin E1. Behav. Neurosci 1984; 98: 858–867
   PubMedGoogle Scholar
• Loghmanee F., Tobak M. Fatal malignant hyperthermia associated with recreational cocaine and alcohol abuse. Am. J. Forensic Med. Pathol 1986; 7: 246–248
   PubMedGoogle Scholar
• Ritchie J. M., Greene N. M. Local anesthetics. The Pharmacological Basis of Therapeutics6th ed., A. G. Gilman, L. S. Goodman, A. Gilman. Macmillan, New York 1980; 300–320
   Google Scholar
• Davidoff R. A. Pharmacology of spasticity. Neurology 1978; 28: 46–51
   PubMed Web of Science ®Google Scholar